Show simple item record

dc.contributor.authorO'Donnell, Jeffrey A.
dc.contributor.authorWu, Mark
dc.contributor.authorCochrane, Niall H.
dc.contributor.authorBelay, Elshaday
dc.contributor.authorMyntti, Matthew F.
dc.contributor.authorJames, Garth A.
dc.contributor.authorRyan, Sean P.
dc.contributor.authorSeyler, Thorsten M.
dc.date.accessioned2022-11-17T16:03:40Z
dc.date.available2022-11-17T16:03:40Z
dc.date.issued2022-03
dc.identifier.citationO'Donnell, Jeffrey A., Mark Wu, Niall H. Cochrane, Elshaday Belay, Matthew F. Myntti, Garth A. James, Sean P. Ryan, and Thorsten M. Seyler. "Efficacy of Common Antiseptic Solutions Against Clinically Relevant Planktonic Microorganisms." Orthopedics 45, no. 2 (2022): 122-127.en_US
dc.identifier.issn0147-7447
dc.identifier.urihttps://scholarworks.montana.edu/xmlui/handle/1/17380
dc.description.abstractProsthetic joint infections (PJIs) are among the most devastating complications after joint replacement. There is limited evidence regarding the efficacy of different antiseptic solutions in reducing planktonic microorganism burden. The purpose of this study was to test the efficacy of different antiseptic solutions against clinically relevant planktonic microorganisms. We designed an experiment examining the efficacy of several antiseptic solutions against clinically relevant planktonic microorganisms in vitro. Regarding planktonic microorganisms, povidone-iodine had 99.9% or greater reduction for all microorganisms tested except for methicillin-resistant Staphylococcus aureus, which was reduced by 60.44%. Irrisept (Irrimax Corp) had 99.9% or greater reduction for all microorganisms except Staphylococcus epidermidis (98.31%) and Enterococcus faecalis (48.61%). Bactisure (Zimmer Surgical Inc) had 99.9% or greater reduction for all microorganisms tested. Various measures exist for PJI prevention, one of which is intraoperative irrigation. We tested irrigants against clinically relevant planktonic microorganisms in vitro and found significant differences in efficacy among them. Further clinical outcome data are necessary to determine whether these solutions can impact PJI in vivo. [Orthopedics. 2022;45(2):122–127.]en_US
dc.language.isoen_USen_US
dc.publisherSLACK, Inc.en_US
dc.rightscopyright SLACK, Inc. 2022en_US
dc.rights.urihttps://marketplace.copyright.com/rs-ui-web/mp/advanced-search/journal/resulten_US
dc.subjectantiseptic solutionsen_US
dc.subjectclinically relvenat planktonicen_US
dc.subjectplanktonic microorganismsen_US
dc.titleEfficacy of Common Antiseptic Solutions Against Clinically Relevant Planktonic Microorganismsen_US
dc.typeArticleen_US
mus.citation.extentfirstpage1en_US
mus.citation.extentlastpage7en_US
mus.citation.issue2en_US
mus.citation.journaltitleOrthopedicsen_US
mus.citation.volume45en_US
mus.identifier.doi10.3928/01477447-20211227-05en_US
mus.relation.collegeCollege of Engineeringen_US
mus.relation.departmentCenter for Biofilm Engineering.en_US
mus.relation.universityMontana State University - Bozemanen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record


MSU uses DSpace software, copyright © 2002-2017  Duraspace. For library collections that are not accessible, we are committed to providing reasonable accommodations and timely access to users with disabilities. For assistance, please submit an accessibility request for library material.